Cell line · CVCL_1702
Papers42
1 to 20 of 42
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| RAS inhibition limits oncogenic signaling and tumorigenesis in neuroblastoma regardless of RAS mutational status | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A guide to selecting high-performing antibodies for Netrin-1 (UniProt ID: O95631) for use in western blot and immunoprecipitation. | F1000Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. | Cancer Discov | 2021 | Its Methods give the RRID and name the line | PubMed | |
| YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling. | Cancer Res | 2019 | Its Methods give the RRID and name the line | PubMed | |
| ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. | Cancer Cell | 2019 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1702/papers